Welcome to Cabometyx.eu website. This website is intended for EU Healthcare professionals only.
Please confirm below that you are a registered healthcare professional.
CABOMETYX® is a small molecule that inhibits multiple receptor tyrosine kinases implicated in tumour growth and angiogenesis, pathologic bone remodelling, drug resistance and metastatic progression of cancer.1 Please select an indication to find out more.
CABOMETYX® (cabozantinib) for the treatment of advanced renal cell carcinoma:1
• In treatment-naïve adults with intermediate or poor risk
• In adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
CABOMETYX® (cabozantinib) for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.1
1. CABOMETYX® Summary of Product Characteristics. View the CABOMETYX®SmPC
If you do not wish to proceed, please close this tab to return to the congress page.